Navigation Links
Escalon® Reports Fiscal 2010 Results

WAYNE, Pa., Sept. 28 /PRNewswire-FirstCall/ -- Escalon Medical Corp. (Nasdaq: ESMC) today announced results for its fiscal year ended June 30, 2010.  

Consolidated product revenue from continued operations for fiscal 2010 increased approximately 0.2% to $30,657,000, compared with $30,600,000 in the prior fiscal year.  The Company experienced an increase related to the Company's Drew and Trek business units, which increased approximately 7.3% and 2.8%, respectively, offset by sales decreases in the Sonomed and EMI business units of 12.2% and 8.5%, respectively.  As discussed below, the Company's Escalon Vascular business assets were sold during fiscal 2010.

The Company reported a fiscal 2010 net loss of $(414,000), which includes discontinued operations income of $3,474,000, or $(0.06) per diluted share, compared with net loss of $(12,965,000), or $(1.81) per diluted share, in the prior year.Cost of goods sold as a percentage of product revenue from continued operations decreased to approximately 56.9% of revenues during the fiscal year ended June 30, 2010, as compared to approximately 59.1% of product from continued operations revenue from continued operations for the prior fiscal year. Cost of goods sold in the Drew business segment was approximately 57.4% of product revenue during the fiscal year ended June 30, 2010, as compared to approximately 62.0% in the prior fiscal year.  The aggregate cost of goods sold as a percentage of product revenue of the Sonomed, EMI and Medical/Trek business units during fiscal year ended June 30, 2010 increased to approximately 56.0% of product revenue from approximately 55.1% in the prior fiscal year.

Operating expenses from continued operations increased approximately 7.8% during the fiscal year ended June 30, 2010 as compared to the prior fiscal year.  This was due to increased marketing, general and administrative expenses of 20.2% offset by a 41.8% decrease in research and development expenses related to the decision to drastically reduce Sonomed and Drew's research and development department.

Recap of 2010Richard J. DePiano, Chairman and Chief Executive Officer, commented, "Given the difficult economic times both domestically and internationally we have been able to maintain our level of revenue through fiscal 2010. While the resulting loss is still disappointing to us, we are encouraged by the trend our divisions have been experiencing."  

"The Sonomed business segment continues to experience a decrease in volume related to the global economic downturn, but overall profitability at Sonomed increased during the fiscal year ended June 30, 2010."  Mr. DePiano further stated that, "Sonomed's customers are hard pressed to add additional or upgraded capital equipment at this time.  While the troubling economic conditions continued throughout fiscal 2010, Sonomed was forced to increase sales discounts to Sonomed's foreign distributors."

"Product revenue decreased $176,000, or 8.5%, in the EMI business segment when compared to the last fiscal year.  The reduction is related to a general decline in the purchase of capital equipment by Digital's customers related to the overall economic climate. The EMI product offering of digital imaging systems continues to expand.  Further, EMI's Web-Based AXIS™ Image Management System is gaining increased market acceptance. AXIS™ seamlessly integrates ophthalmic diagnostic images from different sources into a single searchable database to facilitate ease of review, aid in identifying trends over time across multiple imaging modalities and improve practice efficiency," Mr. DePiano stated.

"In the Drew business unit, product revenue increased $1,318,000, or 7.3%, as compared to last fiscal year.  The increase in product revenue is primarily due to the acquisition of Biocode in December 2008. The year ended June 30, 2010 includes 12 months of Biocode operations, as compared to six months in the prior period. The remainder of the increase is primarily due to strong sales of Drew's Drew-3," Mr. DePiano stated.

As previously reported Escalon divested of its SMARTNEEDLE and pd ACCESS Doppler guided needle product lines to Vascular Solutions, Inc.  in April 2010.  The sales price was $5,750,000, comprised of cash of $5,000,000 at closing and $750,000 payable in cash upon the successful completion of the transfer of the manufacturing to Vascular Solutions, plus a one time earn-out payment in an amount equal to 25% of the net sales of the VascuView TAP products sold between July 1, 2010 and June 30, 2011.   The manufacturing transfer was completed within four months. During those four months, Escalon continued to manufacture product in its Wisconsin facility under a supply agreement concurrently entered into with Vascular Solutions.

As a business, Escalon Vascular Access had matured over the eleven years under Escalon ownership. Management's goals to develop a strong presence in the catheter laboratory market, to achieve proof of concept for several other applications and to add visual ultrasound to the product portfolio were realized up to and during fiscal 2010.

In the Medical/Trek business unit, product revenue increased $35,000, or 2.8%, to $1,297,000 during the year ended June 30, 2010 as compared to the last fiscal year. The increase in Medical/Trek product revenue is attributable to Medical/Trek's product line of Ispan Intraocular gases and fiber optic light sources.

Non-GAAP MeasuresThe Company is providing certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP net loss and non-GAAP loss per fully diluted share.

Specifically, the Company believes the non-GAAP measures provide useful information to both management and investors by isolating certain expenses, gains and losses that may not be indicative of its core operating results and business outlook. In addition, the Company believes non-GAAP measures that exclude stock-based compensation expense enhance the comparability of results against prior periods.

The Company's reference to these non-GAAP measures should be considered in addition to results prepared under current accounting standards, but are not a substitute for, nor superior to, GAAP results. These non-GAAP measures are provided to enhance investors' overall understanding of the Company's current financial performance and provide further information for comparative purposes due to depreciation and amortization and stock based compensation.

The non-GAAP measures and the reconciliation to the most directly comparable GAAP measure of all non-GAAP measures are as follows:Year Ended June 30,20102009Net loss from continuing operations

(3,888,214)$   (13,377,733)Net Income from discontinued operations

412,697Net loss

(413,863)$   (12,965,036)Non-GAAP adjustments:Goodwill impairment

9,525,550Stock based compensation

263,729Depreciation and amortization

742,460Total adjustments

,531,739Non-GAAP adjusted income (loss)

(2,433,297)Shares used in computing basic and fully diluted earnings per share

7,526,4307,137,541Non-GAAP adjusted income (loss)  per fully diluted share

(0.34)Founded in 1987, the Company ( develops, markets and distributes ophthalmic diagnostic, surgical and pharmaceutical products. Drew Scientific, which operates as a separate business unit, provides instrumentation and consumables for the diagnosis and monitoring of medical disorders in the areas of diabetes, cardiovascular diseases and hematology, as well as veterinary hematology and blood chemistry. The Company seeks to utilize strategic partnerships to help finance its development programs and is also seeking acquisitions to further diversify its product line to achieve critical mass in sales and take better advantage of the Company 's distribution capabilities, although such partnerships or acquisitions may not occur. The Company has headquarters in Wayne, Pennsylvania and operations in Long Island, New York, New Berlin, Wisconsin, Lawrence, Massachusetts, Dallas, Texas, Waterbury, Connecticut, Miami, Florida, Barrow-in-Furness, U.K. and Le Rheu, France.

Note:  This press release contains statements that are considered forward-looking under the Private Securities Litigation Reform Act of 1995, including statements about the Company's future prospects. These statements are based on the Company's current expectations and are subject to a number of uncertainties and risks, and actual results may differ materially. The uncertainties and risks include whether the Company is able to:

  • implement its growth and marketing strategies, improve upon the operations of the Company business units, including the ability to make acquisitions and the integration of any acquisitions it may undertake, if any, of which there can be no assurance,
  • implement cost reductions,
  • generate cash,
  • identify, finance and enter into business relationships and acquisitions.  

  • Other factors include uncertainties and risks related to:

  • new product development, commercialization, manufacturing and market acceptance of new products,
  • marketing acceptance of existing products in new markets,
  • research and development activities, including failure to demonstrate clinical efficacy,
  • delays by regulatory authorities, scientific and technical advances by the Company or third parties,
  • introduction of competitive products,
  • ability to reduce staffing and other costs and retain benefit of prior reductions
  • third party reimbursement and physician training,
  • the effects of asset or other business dispositions and divestments, and
  • general economic conditions.

  • Further information about these and other relevant risks and uncertainties may be found in the Company's reports and its other filings with the Securities and Exchange Commission, all of which are available from the Securities and Exchange Commission as well as other sources.

    —Financial Tables Follow—ESCALON MEDICAL CORP. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONSFor the Years Ended June 30,201020092008Net revenues:Product revenue$30,656,518$30,600,177$25,869,540Other revenue985,061132,807222,075Revenues, net31,641,57930,732,98426,091,615Costs and expenses:  Cost of goods sold17,442,81618,097,77715,771,685  Marketing, general and administrative15,692,08713,060,52812,408,561  Research and development1,893,1823,255,6343,798,374  Goodwill impairment09,525,5509,574,655Total costs and expenses35,028,08543,939,48941,553,275Income (loss) from operations(3,386,506)(13,206,505)(15,461,660)Other (expense) and income  Gain on sale of assets091,8710  Equity in Ocular Telehealth Management, LLC(74,911)(65,387)(88,206)  Interest income28518,562299,538  Interest expense(427,083)(216,274)(11,827)Total other income (expense)(501,709)(171,228)199,505Net income  from continuing operations before taxes(3,888,215)(13,377,733)(15,262,155)Provision for income taxes00134,990Net income (loss) from continuing operations(3,888,215)(13,377,733)(15,397,145)Net income from discontinued operations,including gain on disposal of $ 3,493,311 during 2010 3,474,351412,697337,502Net loss$ (413,864)$(12,965,036)$(15,059,643)Net income (loss) per share   Basic:Continuing operations$ (0.52)$ (1.87)$ (2.41)Discontinued operations0.460.060.05Net  income (loss) $ (0.06)$ (1.81)$ (2.36)   Diluted:Continuing operations$ (0.52)$ (1.87)$ (2.41)Discontinued operations0.460.060.05Net income (loss) $ (0.06)$ (1.81)$ (2.36)Weighted average shares - basic7,526,4307,137,5416,389,008Weighted average shares - diluted7,526,4307,137,5416,389,008SELECTED BALANCE SHEET DATA:At June 30,20102009Balance Sheet Data:(Amounts in thousands)Cash and cash equivalents$3,342$1,810Working capital $10,750$10,713Total assets$22,007$25,055Short term debt$1,254$1,375Long-term debt, net of current portion

    $2,916$4,741Total liabilities$9,942$12,617Accumulated deficit($56,646)($56,233)Shareholders' equity$12,065$12,439

    SOURCE Escalon Medical Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results
    2. Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports
    3. Enobia Reports Positive Results For Phase II Trial of ENB-0040 in Juvenile Hypophosphatasia
    4. Corgenix Reports Fiscal 2010 Financial Results
    5. Biodel Reports Research Progress in Poster Session on Short-Acting Insulins at 46th EASD Annual Meeting
    6. Elsevier Launches International Journal of Surgery Case Reports
    7. J.D. Power and Associates Reports: As Consumers Shoulder More Healthcare Expenses, Cost Increasingly Drives Overall Customer Satisfaction With Pharmacies
    8. 12-Month Study Reports Efficacy Rates for AMS Elevate Apical and Posterior Prolapse Repair System
    9. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
    10. Cyberonics Reports Inducement Equity Awards Under NASDAQ Listing Rule 5635(c)(4)
    11. Assured Pharmacy Reports Same Store Sales for the Month of August 2010
    Post Your Comments:
    (Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
    (Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
    (Date:9/28/2017)... WASHINGTON , Sept. 28, 2017 Cohen ... to advance the use of wearable and home sensors ... brain disorders. Early Signal Foundation, a nonprofit organization focused ... populations, will provide an affordable analytical system to record ... ...
    Breaking Medicine Technology:
    (Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
    (Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
    (Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), creator ... tool, and the Cancer Patient Education Network (CPEN), an independent professional organization that ... new strategic alliance. , As CPEN’s strategic partner, HLI will help support ...
    Breaking Medicine News(10 mins):